Stay updated on Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:25:35.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update or modification in the study details related to the efficacy and safety evaluation of pembrolizumab + epacadostat vs pembrolizumab + placebo for recurrent or progressive metastatic urothelial carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:47.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes additional details about eligibility criteria, such as general health condition or prior treatments, and provides a link for more information about clinical research.
    Difference
    13%
    Check dated 2024-05-22T21:03:14.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:45:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial page.